ABSTRACT
The need to verify sensitization to mycotic allergens in children with allergic bronchopulmonary diseases is due to the severity of their clinical course, the high frequency of complications, and the inadequate efficiency of conventional treatment regimens. The sensitivity of most techniques used in clinical practice to estimate the level of specific artibodies to mycotic antigens is inadequately high. Recently clinically introduced high-technology diagnostic methods allow one to attack the problem at a qualitatively new level. The application of one of these methods, namely the highly sensitive semiautomatic diagnostic technology ImmunoCAP, permits the determination of the rates of IgE- and IgG-associated specific immune reactions in children with allergic respiratory diseases.
